Clinical Trial Search

Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants

Primary: Number of Subjects With Single Negative Polymerase Chain Reaction (PCR) Result and 3 Negative Culture Assays — 96.6 percentage of participants

Primary: Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol Population — 457; 487; 182; 187 participants

Primary: MRSA Transmission — 0.20; 0.02; 0.11; 0.01 Proportion of swabs positive for MRSA

Primary: The Presence of MRSA on Repeated Swabs to Assess the Efficacy of These Medications on Clearing MRSA Colonization — 12; 14; 0 Participants

Primary: Number of Participants With Recurrent Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization — 2; 3 Participants

Primary: Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) Population — 84.1; 79.9…

Primary: Incidence of Skin and Soft Tissue Infection (SSTI) — 303; 439; 461 participants

Primary: Number of Participants Eradicated of S. Aureus Carriage - 1 Month After Intervention — 24; 35; 35; 34 Participants

Primary: Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture — 2; 3 Participants

Primary: Time to MRSA Infection — 67; 98; 68; 98 Participants — p=0.026

Primary: Recurrent Infection — 1; 3; 1 participants

Primary: Number of Participants With Incidence of SSTI at 3 Months After Decolonization — 23; 23 Participants — p=0.757

Primary: Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Clinical Success at Test of Cure (TOC) — 45; 16; 2 Participants

Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score

Primary: Number of Participants With Antibiotic Usage at the Time of the ED Visit — 97; 96 Participants

Primary: Re-infection With S. Aureus — 10; 11; 0; 0 participants with S. aureus re-infection — p=0.356

Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants

Primary: Time to 30-day Mortality — 15; 14 days

Primary: Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP Population — 95; 81; 70; 93 Participants…

Primary: Clinical Response at Test of Cure (TOC) — 86.2; 80.0; 0.0; 6.9 Percentage of participants

Primary: Recurrence of Cutaneous Abscess — 5; 7 Participants

Primary: Clinical Improvement at the 48-72 Hour Clinical Follow-up — 94; 97 participants

Primary: Number of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline — 72; 35 Participants

Primary: Number of Participants With MRSA Carriage at 1 Week Post Decolonization With Retapamulin or Placebo — 2; 13 Participants — p=0.0004

Primary: Total Number of MDRO (Multidrug Resistant Organisms) Isolated — 1299; 1732 Total Number of MDRO isolates — p=<0.05

Primary: Acquisition of Methicillin-resistant Staph Aureus (MRSA) Colonization or Infection — 9; 10 participants — p=>0.05

Primary: Medically Attended Skin and Soft Tissue Infections (MA-SSI) — 20.9; 17 percentage of partipants

Primary: Proportion of Participants With MRSA Clearance — 8; 4 Participants — p=0.320

Primary: Surgical Site Infections Occurring Within 12 Months of Surgical Procedure — 0; 5 participants